Still waiting form madamswr's much vaunted joint economic research on shorting of biotechs as indicator in ASX of buys.
We've got Tulip and South Sea bubbles. We've got references to Resmed which is Nasdaq listed.
We've got a generalised rave about shorting. NOthing specific. NOthing like a joint economic research report on the topic.
Why? It's looking like a stupid idea, that's why.
Were you hoping we'd forget your (at the time rather impressive looking) promise? Did it impress anyone? Not me.
Up up up down down down, page-25
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |